Department Molecular Cell Biology Weizmann Institute of Science







Laboratory of David Givol

Selected Publications

(out of 267)


  1. Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D, D'Orazi G.
    HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.
    Cancer Biol Ther. 15;13(4):198-205 (2012).

  2. Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G.
    Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation.
    Oncotarget. Dec;2(12):1191-202 (2011).

  3. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D'Orazi G, Givol D, Amariglio N.
    Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function.
    Int J Cancer. Sep 19 (2011).

  4. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D'Orazi G.
    Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
    Cell Cycle. 10(10):1679-89 (2011).

  5. Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G.
    Zinc downregulates HIF-1a and inhibits its activity in tumor cells in vitro and in vivo.
    PLoS One. 5(12):e15048 (2010).

  6. Nardinocchi L, Puca R, Givol D, D'Orazi G.
    HIPK2-A therapeutical target to be (re)activated for tumor suppression: Role in p53 activation and HIF-1alpha inhibition.
    Cell Cycle. 4;9(7) (2010).     [pdf]

  7. Yakubov E, Rechavi G, Rozenblatt S, Givol D.
    Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors.
    Biochem Biophys Res Commun. 26;394(1):189-93 (2010).

  8. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D'Orazi G.
    Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.
    Free Radic Biol Med. 15;48(10):1338-46 (2010).

  9. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G.
    HIPK2 modulates p53 activity towards pro-apoptotic transcription.
    Mol Cancer. 14;8:85 (2009).     [pdf]

  10. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G.
    Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
    PLoS One. 28;4(8):e6819 (2009).

  11. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D and D'Orazi G.
    Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
    Exp Cell Res. 315(1):67-75 (2009).

  12. Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D and Murakami S.
    FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Hum Mol Genet. 18(2):227-240 (2009).     [pdf]

  13. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G.
    Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockkown.
    Cancer Res. 68(10):3707-3714 (2008).      [pdf]

  14. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G.
    PML, YAP, and p73 are Components of a Proapoptotic Autoregulatory Feedback Loop.
    Mol Cell, 32, 803-814 (2008).

  15. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.
    Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.
    Leukemia 20(12):2147-2154 (2006).      [pdf]

  16. Golan-Mashiach M, Dazard JE, Gerecht-Nir S, Amariglio N, Fisher T, Jacob-Hirsch J, Bielorai B, Osenberg S, Barad O, Getz G, Toren A, Rechavi G, Itskovitz-Eldor J, Domany E, Givol D.
    Design principle of gene expression used by human stem cells: implication for pluripotency.
    FASEB J 19:147-149 (2005).      [pdf]

  17. Kannan D, Rechavi G, Givol D.
    p53's dilemma in transcription: Analysis by microarrays.
    Chapter 19 in p53 Book, ed. Hupp T., Eureka Publisher, pp.1-17 (2004).

  18. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B.
    Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    Genes Dev. 18, 290-305 (2004).

  19. Lotem J., Gal H., Kama R., Amariglio N., Rechavi G., Domany E., Sachs L. and Givol D.
    Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes.
    Proc. Natl. Acad. Sci. USA, 2003.     [pdf]     Supplementary Data

  20. Dazard J-E., Gal H., Amariglio N., Rechavi G., Domany E. and Givol D.
    Genome-Wide Comparison of Keratinocyte and Squamous Cell Carcinoma Response to UVB Irradiation; Implication for Skin and Epithelial Cancer Development.
    Oncogene, in press, 2003.     [pdf]     Supplementary Data

  21. Givol D., Veraragavan P.E. and Lonai P.
    Molecular and cellular biology of FGF signaling. Chapter to the Book Molecular Basis of Inborn Errors of Development.
    Oxford University Press, in press, 2003.

  22. Fontemaggi G., Kela I., Amariglio N., Rechavi G., Krishanmurthy J., Strano S., Sacchi A., Givol D. and Blandino G.
    Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.
    J. Biol. Chem., 277, 43359-68, 2002.     [pdf]     Supplementary Data

  23. Rozenfeld-Granot G., Krishanmurthy J., Kannan K., Toren A., Amariglio N., Givol D. and Rechavi G.
    A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1.
    Oncogene, 21, 1469-76, 2002.     [pdf]

  24. Amsterdam A., Kannan K., Givol D., Yoshida Y., Tajima K. and Dantes A.
    Apoptosis of granulosa cells and female infertility in achonfroplastic mice expressing mutant fibroblast growth factor receptor 3G374R.
    Mol. Endocrinol., 15, 1610-23, 2001.     [pdf]

  25. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D.
    DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1.
    Oncogene, 20, 3449-3455, 2001a.     [pdf]     Supplementary Data

  26. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D.
    DNA microarrays identification of primary and secondary target genes regulated by p53.
    Oncogene, 20, 2225-34, 2001b.     [pdf]     Supplementary Data

  27. Kannan K., Rechavi G., Amariglio N. and Givol D.
    Profile of Gene Expression Regulated by Inducible p53 - Connection to the TGF-B Family.
    FEBS Lett., 470, 77-82, 2000.     [pdf]

  28. Kannan K. and Givol D.
    FGF receptor mutations, Dimerization syndromes Cell Growth Suppression and Animal Models.
    IUBMB Life, 49, 197-205, 2000.    

  29. Katzir E. and Givol D.
    Entering the kitchen of the Almighty: Achievement and challenges of modern molecular genetics. In Hebrew.
    Ramot Publishers, 1999.

  30. Wang Y., Spatz M., Kannan K., Hayk H., Avivi A., Gorivodsky M., Pines M., Yayon A., Lonai P. and Givol D.
    A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
    Proc. Natl. Acad. Sci. USA, 96, 4455-4460, 1999.     [pdf]

  31. Wang Y., Blandino G. and Givol D.
    Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin.
    Oncogene, 18, 2643-2649, 1999.     [pdf]

  32. Wang Y., Blandino G., Oren M. and Givol D.
    Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti cancer drugs.
    Oncogene, 17, 1923-1930, 1998.     [pdf]

  33. Givol I., Givol D. and Hughes S.H.
    Overexpression of p21waf arrests the growth of chicken embryo fibroblast that overexpress E2F1.
    Oncogene, 16, 3115-3122, 1998.     [pdf]

  34. Michieli P., Li W., Lorenzi M.V., Miki T., Zakut R., Givol D. and Pierce J.H.
    Inhibition of oncogene-mediated transformation by ectopic expression of p21waf in NIH 3T3.
    Oncogene, 12, 775-784, 1996.

  35. Zakut R. and Givol D.
    The tumor suppression function of p21waf is contained in its N-terminal half ("half-waf").
    Oncogene, 11, 393-395, 1995.

  36. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E. and Givol D.
    Induction of WAF1/CIP1 by a p53-independent pathway.
    Cancer Res., 54, 3391-3395, 1994.

  37. Orr-Urtreger A., Bedford M.T., Burakova T., Arman E., Zimmer Y., Yayon A., Givol C. and Lonai P.
    Developmental localization of the splicing alternatives of fibroblast growth factor receptor 2 (FGFR2).
    Developmental Biology, 158, 475-486, 1993.     [pdf]

  38. Lev S., Yarden Y. and Givol D.
    Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor.
    J. Biol. Chem., 267, 15970-7, 1992.    

  39. Yayon A., Zimmer Y., Hong S.G., Yarden Y., Avivi A. and Givol D.
    A confined variable region confers ligand specificity to fibroblast growth factor receptors: Implications for the origin of the immunoglobulin fold.
    EMBO J., 11, 1885-1890, 1992.

  40. Orr-Urtreger A., Givol D., Yayon A., Yarden Y. and Lonai P.
    Developmental expression of two murine fibroblast growth factor receptors, flg and bek.
    Developmental Biology, 113, 1419-34, 1991.    

  41. Givol D.
    The minimal antigen-binding fragment of antibodies-Fv fragment.
    Mol. Immunol., 28, 1379-1386, 1991.

  42. Sap J., D'Eustachio P., Givol D. and Schlessinger J.
    Cloning and expression of a widely expressed receptor tyrosine phosphatase.
    Proc Natl Acad Sci U S A., 87, 6112-6, 1990.

  43. Lax I., Bellot F., Howk R., Ullrich A., Givol D. and Schlessinger. J.
    Functional analysis of the ligand binding site of the EGF-receptor.
    EMBO J., 8, 421-427, 1989.

  44. Ruta M, Burgess W, Givol D, Epstein J, Neiger N, Kaplow J, Crumley G, Dionne C, Jaye M, Schlessinger J.
    Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG).
    Proc Natl Acad Sci U S A., 86, 8722-6. 1989.

  45. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM.
    Localization of gene for human p53 tumour antigen to band 17p13.
    Nature, 320, 84-85, 1986.

  46. McBride O.W., Merry D. and Givol D.
    The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).
    Proc Natl Acad Sci U S A., 83, 130-4, 1986.

  47. McBride O.W., Merry D.E., Oren M. and Givol D.
    Human p53 cellular antigen is on chromosome 17p13.
    Cytogenetics and Cell Genetics, 40, 694, 1985.

  48. Zakut-Houri R., Bienz-Tadmor B., Givol D. and Oren M.
    Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.
    EMBO J., 4, 1251, 1985.

  49. Chiu I.M., Reddy E.P., Givol D., Robbins K.C., Tronick S.R. and Aaronson S.A.
    Nucleotide sequence analysis identifies the human c-sis protooncogene as a structural gene for PDGF.
    Cell, 37, 123, 1984.

  50. Zakut-Houri R., Oren M., Bienz B., Lavie V., Hazum S. and Givol D..
    A single gene and a pseudogene for the cellular tumor antigen p53.
    Nature, 306, 594-597, 1983.

  51. Cohen J.B., T. Ungar, G. Rehavi, E. Canaani E. and Givol D..
    Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas.
    Nature, 306, 797-799, 1983.

  52. Rechavi G., Givol D. and Canaani E.
    Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element.
    Nature, 300, 607-611, 1982.

  53. Givol D., Zakut R., Effron K., Rechavi G., Ram D. and Cohen J.B.
    Diversity of germ-line immunoglobulin VH genes.
    Nature, 292, 426, 1981.

  54. McReynolds L., O'Malley B.W., Nisbert A.D., Fothergill J.E., Givol D., Fields S., Robertson M. and Brownlee G.G.
    Sequence of chicken ovalbumin messenger RNA.
    Nature, 273, 723, 1978.

  55. Wilchek M. and Givol D.
    Affinity cross-linking of heavy and light chain of the myeloma protein MOPC-315.
    Methods in Enzymology Vol., 46, 501, 1977.

  56. Dwek R.A., Wain-Hobson S., Dower S., Gettins P., Sutton B., Perkins S.J. and Givol D.
    Structure of an antibody combining site by magnetic resonance.
    Nature, 266, 31, 1977.

  57. Hochman J., Inbar D. and Givol D.
    An active antibody fragment (Fv) composed of the variable portions of heavy and light chains.
    Biochemistry, 12, 1130, 1973.

  58. Inbar D., Hochman J. and Givol D.
    Localization of antibody combining sites within the variable portion of heavy and light chains.
    Proc. Natl. Acad. Sci. USA, 69, 2659, 1972.

  59. Wilchek M., Bocchini V., Becker M. and Givol D.
    A general method for the specific isolation of peptides containing modified residues using insoluble antibody column.
    Biochemistry, 10, 2828, 1971.

  60. Strausbauch P., Sulica A. and Givol D.
    General Method for the detection of cells producing antibodies against haptens and proteins.
    Nature, 227, 553, 1970.

  61. Givol D. and Porter R.R.
    The C-terminal peptide of the heavy chain of rabbit beta-globulin.
    Biochem. J., 97, 32C, 1965.

  62. Givol D., De Lorenzo F., Goldberger R.F. and Anfinsen C.B.
    Disulfide interchange and the three-dimensional structure of proteins.
    Proc. Natl. Acad. Sci. USA, 53, 676, 1965.

  63. Givol D. and Sela M..
    A comparison of fragments of rabbit antibodies and normal gamma-globulin by the peptide map technique.
    Biochemistry, 3, 451, 1964.

TOP

Back to David Givol's Home Page


Weizmann Institute of Science
Department Molecular Cell Biology
76100 Rehovot, Israel
Phone: +972-8-934-3634
Fax:     +972-8-934-4125